Seoul, South Korea

Yun Ju Nam


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2018-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Inventor Yun Ju Nam

Introduction

Yun Ju Nam is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of therapeutic agents, particularly in the treatment of chronic myelogenous leukemia and cancer. With a total of two patents to his name, his work is recognized for its potential to improve patient outcomes.

Latest Patents

Yun Ju Nam's latest patents include innovative therapeutic agents designed to combat drug resistance and side effects. The first patent focuses on CML therapeutic agents that utilize 1,6-disubstituted indole compounds. This invention aims to provide a more effective treatment for chronic myelogenous leukemia by reducing drug resistance and side effects. The second patent involves 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives, which serve as protein kinase inhibitors. This compound is recognized as an anticancer agent, containing the compound as an active ingredient and an intermediate for its preparation.

Career Highlights

Yun Ju Nam is affiliated with the Korea Institute of Science and Technology, where he conducts his research and development. His work is characterized by a strong focus on creating effective therapeutic solutions for serious health conditions.

Collaborations

Yun Ju Nam collaborates with notable colleagues, including Tae Bo Sim and Ho Jong Yoon, who contribute to his research endeavors.

Conclusion

Yun Ju Nam's innovative work in developing therapeutic agents showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of chronic myelogenous leukemia and cancer, highlighting the importance of continued research in this field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…